Poor “Site Effect” Profile? Neurochem Reports Inconclusive Alzheimer’s Data For Alzhemed
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm will base Alzhemed next steps on Special Advisory Board analysis of North American trial data.
You may also be interested in...
Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline
Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.
Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline
Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.
Neurochem’s Alzhemed On Fast Track For Alzheimer’s Disease
Firm has August meeting scheduled with FDA to review Phase III data and discuss statistical review of current and future results.